Program of the 9th AMR Conference
Preliminary overview of sessions. Titles are subject to change. All moderators and speakers to be announced.
Pre-conference meetings
Tuesday, 5 March 2024
Conference Day 1
Tuesday, 25 February 2025
Conference Day 2
Wednesday, 26 February 2025
Pre-conference meetings
Tuesday, 5 March 2024 | Venue tbd
The pre-conference meetings are not an integral part of the AMR Conference. However, when registering for the conference, you can indicate your interest to participate. The organizers will inform you about the acceptance of your participation shortly before the conference.
09:30 – 15:30
Workshop – Phage Therapy: What’s New and What’s Next?
This interactive workshop aims to delve into the development of a sustainable phage therapy value chain, emphasizing the progress, challenges and opportunities in phage therapy. Sessions will be held on scientific developments, clinical research, and phage manufacturing. Participants will also explore intellectual property strategies and engage in discussions about the global regulatory landscape. In addition, the event will include start-up showcases and an investor panel to discuss funding options and investment strategies. The workshop provides a platform for experts, entrepreneurs, and investors to explore the future of phage therapy. Number of participants will be limited.
Organized by
Fully booked
16:00 – 18:00
Networking meeting
Organized by
Fully booked
Conference Day 1
Tuesday, 25 February 2025 | Congress Center 2nd floor
08:45 – 10:30
BEAM Alliance General Assembly
open only to members of the BEAM Alliance
09:00 – 10:30
Pre-conference workshop
Title tbd
Jointly organized by
Moderator:
Ursula Theuretzbacher (Center for Anti-Infective Agents)
Speakers:
Malcolm Page (Antibiotic Research): “Integrating TPPs and TCPs in discovery strategies”
Kenneth Bradley (F. Hoffmann-La Roche Ltd.): “Data driven decision making in antibiotics preclinical research”
11:00 – 12:00
Opening plenary
Taking action after renewed political commitment
12:00 – 13:30
Lunch break
13:30 – 14:30
Plenary session
Translating AMR clinical needs from local to global
15:00 – 16:00
Parallel sessions
I
Technology corner in diagnostics
II
Remarkable advances in AMR science
III
Pathogen reduction approaches to prevent AMR
16:30 – 17:30
Parallel sessions
I
Financing product development
II
PK/PD approaches to improve the translation of doses to clinic
III
Developing biologics for global purposes
18:00 – 19:30
Start-up pitch
Hosted by
10’000 € award sponsored by
Moderator:
Douglas Häggström (INCATE)
Running order of pitching companies:
- TabriX (presented by Marc Creus)
- BrIgID Biologics (presented by Soumya Palliyil)
- BamA Inhibitor (presented by Till Schäberle)
- Microplate Dx (presented by Stuart Hannah)
- Omnicin Therapeutics (presented by Auke van Heel)
- Obulytix (presented by Yves Briers)
- Tolka AI Therapeutics (presented by Johan Wikstrom)
- Generare (presented by Guillaume Vandenesch)
- Theralia AB (presented by Baris Ata Borsa)
- Puray (presented by Martin Duffner)
- Smartbax (presented by Robert Macsics)
19:30 – 21:30
Evening reception
Conference Day 2
Wednesday, 26 February 2024 | Congress Center 2nd floor
08:30 – 09:30
Plenary session
Past failures, future successes
10:00 – 11:00
Parallel sessions
I
Challenges in diagnostic uptakes
II
Technology update
III
Clinical endpoints: fit-for-purpose?
11:30 – 12:30
Plenary session
Manufacturing is not only a post-marketing topic
12:30 – 14:00
Lunch break
14:00 – 15:00
Parallel sessions
I
Post-development financing
II
The growing threat of sexually transmitted infections
III
Clinical trials: combining drugs, not problems
15:30 – 16:30
Parallel sessions
I
Making the most of external expertise
II
Reaching the right people with the right drug
III
One Health, climate and innovation
17:00 – 18:00
Closing plenary
Communicating on AMR, a simple matter of wording?
and presentation of the poster awards
18:00 – 19:00
Farewell reception
BEAM Alliance program committee
Marc Gitzinger
Florence Séjourné
